medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 2

<< Back Next >>

Acta Med 2021; 19 (2)

Cardiomyopathy due to amyloidosis

Cabrera PD, Díaz GEJ, Rodríguez WFL

Language: Spanish
References: 32
Page: 244-252
PDF size: 199.65 Kb.


ABSTRACT

Cardiac amyloidosis is a disease of scarce clinical suspicion due to its low incidence, however, in recent years and thanks to advances in imaging methods, there has been an increase in diagnosed cases, which is reflected in new treatments for different types of this illness.


REFERENCES

  1. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017; 84 (12 Suppl 3): 12-26.

  2. Flodrova P, Flodr P, Pika T, Vymetal J, Holub D, Dzubak P et al. Cardiac amyloidosis: from clinical suspicion to morphological diagnosis. Pathology. 2018; 50 (3): 261-268.

  3. Di Giovanni B, Gustafson D, Adamson MB, Delgado DH. Hiding in plain sight: cardiac amyloidosis, an emerging epidemic. Can J Cardiol. 2020; 36 (3): 373-383.

  4. Alkhawam H, Patel D, Nguyen J, Easaw SM, Al-Sadawi M, Syed U et al. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options. Acta Cardiol. 2017; 72 (4): 380-389.

  5. Sperry BW, Tang WHW. Amyloid heart disease: genetics translated into disease-modifying therapy. Heart. 2017; 103 (11): 812-817.

  6. Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D et al. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep. 2017; 19 (7): 46.

  7. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018; 18 (Suppl 2): s30-s35.

  8. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019; 6 (6): 1128-1139.

  9. Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018; 43 (1): 10-34.

  10. Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience. Rev Invest Clin. 2012; 64 (6 Pt 2): 604-608.

  11. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017; 135 (14): 1357-1377.

  12. González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017; 38 (24): 1895-1904.

  13. Fontana M, Corovic A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019; 12 (11 Pt 2): 2345-2356.

  14. González-Duarte A, Cárdenas-Soto K, Bañuelos CE, Fueyo O, Dominguez C, Torres B, et al. Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases. Orphanet J Rare Dis. 2018; 13 (1): 107.

  15. Halatchev IG, Zheng J, Ou J. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis. 2018; 10 (3): 2034-2045.

  16. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018; 5 (5): 772-779.

  17. Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018; 18 (1): 221.

  18. Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020; 17 (7): 413-426. Available from: http://dx.doi.org/10.1038/s41569-020-0334-7

  19. Izumiya Y, Takashio S, Oda S, Yamashita Y, Tsujita K. Recent advances in diagnosis and treatment of cardiac amyloidosis. J Cardiol. 2018; 71 (2): 135-143.

  20. López-Sainz A, Hernandez-Hernandez A, Gonzalez-Lopez E, Domínguez F, Restrepo-Cordoba MA, Cobo-Marcos M et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol (Engl Ed). 2021; 74 (2): 149-158.

  21. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019; 6 (5): 1041-1051.

  22. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol [Internet]. 2015; 12 (2): 91-102. Available from: http://dx.doi.org/10.1038/nrcardio.2014.165

  23. Kristen AV, Brokbals E, Aus dem Siepen F, Bauer R, Hein S, Aurich M et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol. 2016; 68 (1): 13-24.

  24. Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020; 13 (6): 1368-1383.

  25. Alexanderson-Rosas E, Escudero-Salamanca M, Garcia-Diaz JA, Alvarez-Santana R, Cano-Zarate R, Mamani-Tito J et al. Light-chain cardiac amyloidosis: A multimodality approach. J Nucl Cardiol [Internet]. 2020; 27 (6): 2432-2435. Available from: https://doi.org/10.1007/s12350-019-02017-y

  26. Aimo A, Rapezzi C, Vergaro G, Giannoni A, Spini V, Passino C et al. Management of complications of cardiac amyloidosis: 10 questions and answers. Eur J Prev Cardiol. 2020: 2047487320920756.

  27. Wolfson AM, Shah KS, Patel JK. Amyloid and the Heart. Curr Cardiol Rep. 2019; 21 (12): 164.

  28. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017; 130 (7): 900-902.

  29. Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia [Internet]. 2019; 33 (2): 531-536. Available from: http://dx.doi.org/10.1038/s41375-018-0262-2

  30. Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018; 93 (9): 1169-1180.

  31. González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol [Internet]. 2020; 267 (3): 703-712. Available from: https://doi.org/10.1007/s00415-019-09602-8

  32. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010; 90 (8): 905-911.




2020     |     www.medigraphic.com